Did You Know...
...that the Eveready Battery began as an invention called the "electric flowerpot," which was a tube with a battery and light bulb inside? The idea was to fasten this gizmo to the side of a flowerpot so it would illuminate the flowers from the bottom. The idea died on the vine and the businessman who licensed the flower pot, Conrad Huber, was left with a pile of useless tubes -- until he found a way to market them as batteries to light the world!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8158419 | Transgenic non-human animals for producing chimeric antibodies The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity. ... | 04/17/2012 |
| 8142778 | Methods of treatment using CTLA-4 antibodies The present invention provides method of treatment using human sequence antibodies against human CTLA-4 linked to a cytotoxic agent. In particular, methods of treating cancer and autoimmune disease are provided. ... | 03/27/2012 |
| 8129508 | Protein purification using HCIC and ion exchange chromatography The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step. ... | 03/06/2012 |
| 8124738 | Human monoclonal antibodies to CD70 The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods ... | 02/28/2012 |
| 8110194 | CTLA-4 antibody dosage escalation regimens A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reac... | 02/07/2012 |
| 8097703 | CD19 antibodies and their uses The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressin... | 01/17/2012 |
| 8088377 | Human monoclonal antibodies against CD30 Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by underg... | 01/03/2012 |
| 8034959 | Methods of treating cancer with an antibody-drug conjugate The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as ot... | 10/11/2011 |
| 8034787 | Enzyme-cleavable prodrug compounds The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are m... | 10/11/2011 |
| 8025882 | Interferon alpha antibodies and their uses The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity o... | 09/27/2011 |
| 8017114 | Human CTLA-4 antibodies and their uses The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. ... | 09/13/2011 |
| 8008449 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods fo... | 08/30/2011 |
| 7977465 | Peptidyl prodrugs and linkers and stabilizers useful therefor The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as ot... | 07/12/2011 |
| 7968586 | Cytotoxic compounds and conjugates The present disclosure provides cytoxic compounds useful as drugs or prodrugs and to drug-cleavable substrate conjugates where the drug and cleavable substrate are optionally linked through a self-immolative linker. ... | 06/28/2011 |
| 7943743 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods... | 05/17/2011 |
| 7939076 | Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 int... | 05/10/2011 |
| 7910798 | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host anim... | 03/22/2011 |
| 7893023 | Prodrugs activated by plasmin and their use in cancer chemotherapy The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The ... | 02/22/2011 |
| 7888484 | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the human... | 02/15/2011 |
| 7847105 | Methods and compounds for preparing CC-1065 analogs A method of forming a CBI CC-1065 analog utilizes NH2 as a starting material, where R3 is H or alkyl and R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy. Intermediates (I) are used and are claimed. ... | 12/07/2010 |
| 7875278 | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides h... | 01/25/2011 |
| 7820399 | Methods for characterizing glycosylation sites The present invention provides methods for isolating and characterizing the glycosylation sites of a glycoprotein, such as a glycosylated antibody. In particular, the methods employ affinity capture, liquid chromatography, and mass spectrometry to determine, for exa... | 10/26/2010 |
| 7816578 | Transgenic transchromosomal rodents for making human antibodies The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies. ... | 10/19/2010 |
| 7816317 | Tripeptide prodrug compounds The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopept... | 10/19/2010 |
| 7790160 | Method of treating CD30 positive lymphomas Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and proteasome inhibitors in combination are disclosed. ... | 09/07/2010 |
| 7771962 | CD10-activated prodrug compounds The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Met... | 08/10/2010 |
| 7744875 | Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided. ... | 06/29/2010 |
| 7741449 | Anti-interferon alpha antibodies The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity o... | 06/22/2010 |
| 7718776 | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detec... | 05/18/2010 |
| 7714016 | Cytotoxic compounds and conjugates with cleavable substrates The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them. ... | 05/11/2010 |
| RE41252 | Peptidyl prodrugs and linkers and stabilizers useful therefor The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as ot... | 04/20/2010 |
| 7696313 | Prodrug compounds with isoleucine The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is clea... | 04/13/2010 |
| 7691962 | Chemical linkers and conjugates thereof The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugat... | 04/06/2010 |
| 7674618 | Expression vector This invention provides nucleic acids and expression vectors, and host cells transformed with the same, for providing high expression of a desired polypeptide. Also provided are methods of using the expression vectors, nucleic acids, and host cells which have been m... | 03/09/2010 |
| 7662381 | Interferon alpha receptor 1 antibodies and their uses The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodie... | 02/16/2010 |
| 7625559 | Antibodies against toxins and uses thereof Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein. ... | 12/01/2009 |
| 7619070 | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the human... | 11/17/2009 |
| 7611702 | TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy. ... | 11/03/2009 |
| 7605238 | Human CTLA-4 antibodies and their uses The present invention provides human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. ... | 10/20/2009 |
| 7601818 | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and par... | 10/13/2009 |
